Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced on March 10, 2014 that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to the use of the Company’s drug candidate, Trimesta™ (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases. Synthetic Biologics Inc (NYSEMKT:SYN) shares after opening at $2.99 on last trade day and at the end of the day closed at $3.13. Company price to cash ratio in past twelve months was calculated as 27.41. Synthetic Biologics Inc (NYSEMKT:SYN) showed a positive weekly performance of 15.07%.
Allscripts Healthcare Solutions (NASDAQ:MDRX) SVP Deborah Snow sold 14,740 shares of Allscripts Healthcare Solutions stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $18.75, for a total value of $276,375.00. Following the completion of the transaction, the senior vice president now directly owns 32,560 shares in the company, valued at approximately $610,500. Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) shares advanced 1.65% in last trading session and ended the day on $19.07. MDRX return on equity ratio is recorded as -8.10% and its return on assets is -4.20%. Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) yearly performance is 39.10%.
TheStreet Quant Ratings rates Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved up 0.68% in last trading session and was closed at $17.65, while trading in range of $16.79 – $18.13. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is 42.22%.
Enzo Biochem, Inc. (NYSE:ENZ) on March 11, 2014 reported across-the-board improved results for the fiscal second quarter ended January 31, 2014 as compared to the corresponding year-ago period. Total revenues improved 3%, with gains in Life Science and Clinical Labs, despite inclement winter weather that impacted laboratory revenues. Enzo Life Sciences operating results showed benefits of strategic realignment, including its emphasis on targeted markets with higher margin products. Enzo Clinical Labs posted operating gains as a result of its emphasis on greater number of high-value assays and new alliances, as well as reduced accounts receivables uncollectible provisions from better collection experience. New alliances are expanding Clinical Labs’ range of esoteric and molecular diagnostics, particularly in women’s health area, a growing specialty for Enzo. Enzo Biochem, Inc. (NYSE:ENZ) weekly performance is 16.80%. On last trading day company shares ended up $4.24. Enzo Biochem, Inc. (NYSE:ENZ) distance from 50-day simple moving average (SMA50) is 30.63%. Analysts mean target price for the company is $5.50.